| pubmed-article:2201653 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2201653 | lifeskim:mentions | umls-concept:C0927232 | lld:lifeskim |
| pubmed-article:2201653 | lifeskim:mentions | umls-concept:C1372798 | lld:lifeskim |
| pubmed-article:2201653 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:2201653 | pubmed:dateCreated | 1990-9-24 | lld:pubmed |
| pubmed-article:2201653 | pubmed:abstractText | Acetyl-levo-carnitine (ALC) is a neuroactive agent. Some studies demonstrate that it modifies cortical electrophysiological responses in animals and man. Foremost, neuronal synchrony appears to be affected. It is thought that ALC is involved in cholinergic neurotransmission although some of its effects may be more complex. Electrophysiological processes involved in cognition may be influenced by ALC: in particular P300, an event-related potential, can be modified. Recent research data in man and monkeys concerning presumed ALC effects on P300 and cognition are summarized. | lld:pubmed |
| pubmed-article:2201653 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2201653 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2201653 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2201653 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2201653 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2201653 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2201653 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2201653 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2201653 | pubmed:issn | 0251-1649 | lld:pubmed |
| pubmed-article:2201653 | pubmed:author | pubmed-author:Bodis-Wollner... | lld:pubmed |
| pubmed-article:2201653 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2201653 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:2201653 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2201653 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2201653 | pubmed:pagination | 109-14 | lld:pubmed |
| pubmed-article:2201653 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2201653 | pubmed:meshHeading | pubmed-meshheading:2201653-... | lld:pubmed |
| pubmed-article:2201653 | pubmed:meshHeading | pubmed-meshheading:2201653-... | lld:pubmed |
| pubmed-article:2201653 | pubmed:meshHeading | pubmed-meshheading:2201653-... | lld:pubmed |
| pubmed-article:2201653 | pubmed:meshHeading | pubmed-meshheading:2201653-... | lld:pubmed |
| pubmed-article:2201653 | pubmed:meshHeading | pubmed-meshheading:2201653-... | lld:pubmed |
| pubmed-article:2201653 | pubmed:meshHeading | pubmed-meshheading:2201653-... | lld:pubmed |
| pubmed-article:2201653 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2201653 | pubmed:articleTitle | Physiological effects of acetyl-levo-carnitine in the central nervous system. | lld:pubmed |
| pubmed-article:2201653 | pubmed:affiliation | Department of Neurology, Mount Sinai Medical Center, New York. | lld:pubmed |
| pubmed-article:2201653 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2201653 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2201653 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:2201653 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
